After Failed Skin Shots, A New Path

After a biologic treatment failed, many people with moderate to severe psoriasis tried another biologic. This study looked at switching after an IL-17 inhibitor did not work. The goal was to learn about moving to an IL-23 inhibitor. Doctors wanted to know how well that switch could work.

The study followed 30 patients for 52 weeks. Each patient had failed one IL-17 inhibitor. Then each was switched to tildrakizumab. The team checked skin scores and patient feelings. They used several measures. They looked at PASI and PGA. They saw response rates at 75, 90, and 100 percent. They also checked DLQI, WHO-5, and TSQM-9. Checks happened at baseline and at weeks 4, 16, and 52.

The team saw fast and lasting improvement. The average PASI score went from 12.2 down to 1.1. At week 52, 88.9 percent reached PASI75. 66.7 percent reached PASI90. 50 percent reached PASI100. 94.4 percent reached a PASI score of 3 or less. DLQI and WHO-5 scores also improved. Satisfaction scores were high.

Dosing was part of the watch. At first, 46.7 percent got 100 mg. Then all patients moved to 200 mg. No patient stayed on 100 mg. The team said this dose change happened often. The study had no group that stayed on 100 mg. So it could not compare the two doses.